BEN-28010 / BenevolentAI - LARVOL DELTA

Discovery of a Potent, Selective, and Brain-Penetrant Checkpoint Kinase 1 Inhibitor, BEN-28010, for the Treatment of Glioblastoma. (PubMed, J Med Chem) - "In vivo pharmacological studies demonstrated efficacy of orally administered 38 in several GBM CDX and PDX models as a monotherapy and in combination with ionizing radiation, including improved overall survival in an intracranially implanted GBM PDX mouse model. Additionally, 38 utilizes an underrepresented aminoimidazole kinase hinge-binding motif that may have broader utility within kinase inhibitor drug discovery."

Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CHEK1

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023 (Businesswire) - "Successfully progressed glioblastoma multiforme (GBM) asset to IND-ready status. BEN-28010 is an oral brain-penetrant CHK1 inhibitor for the treatment of GBM and metastatic brain tumours which completed regulatory IND-enabling studies during the year to plan."

Clinical • Glioblastoma

BenevolentAI: Interim Results for the Six Months Ended 30 June 2023 (Businesswire) - "BEN-28010, a CHK1 inhibitor for Glioblastoma Multiforme (GBM) and metastatic brain tumours, remains on track and is expected to be IND-ready by Q4 2023."

IND • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 (Businesswire) - "BEN-2293...A topical potentially best-in-class PanTrk inhibitor in development to relieve inflammation and rapidly resolve the itch in patients with atopic dermatitis (AD). Completed a Phase IIa study and expect top-line data by the end of March 2023. BEN-8744...An oral peripherally-restricted small molecule PDE10 inhibitor under development as a first-in-class treatment for ulcerative colitis (UC) and with potential for other indications within inflammatory bowel diseases....expect to initiate a Phase I clinical trial in H1 2023. BEN-28010...An orally administered asset under development as a best-in-class treatment for glioblastoma multiforme (GBM). Declared as a clinical candidate in July 2022, with preparation for IND-enabling studies ongoing. The asset could be ready for Phase I studies in 2024."

New P1 trial • P2a data • Atopic Dermatitis • Glioblastoma • Glioma • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Solid Tumor • Ulcerative Colitis

BenevolentAI Interim Results for the Six Months Ended 30 June 2022 (Businesswire) - "BEN-28010 is an orally administered asset we are developing as a best-in-class treatment for glioblastoma multiforme...Preparation for IND-enabling studies ongoing. Subject to positive data the asset will then be ready for Phase I studies in 2024."

New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Oncology